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Abstract
Hypertrophic scar (HTS) is a fibrotic skin disorder that is marked by exces-
sive inflammation and extracellular matrix deposition in response to cutaneous 
traumatic injuries such as burns, lacerations, incisions, and abrasions. HTS has 
various risk factors, available treatments, and treatment effectiveness. Research at 
the basic, translational, and clinical levels are in their infancy compared to fibrotic 
diseases in other organ systems. This chapter will review current in vitro and in vivo 
modeling, and highlight research needs to address gaps in the study of HTS. The fol-
lowing topics will be discussed in the chapter: a. Basic Science Research i. Seminal 
findings ii. Limitations to these models iii. Suggestions for topics of future research 
b. Translational Science Research i. Seminal findings ii. Limitations to these models 
iii. Suggestions for topics of future research c. Clinical Research i. Seminal findings 
ii. Limitations to these models iii. Suggestions for topics of future research.
Keywords: hypertrophic scar, basic and translational research, clinical research
1. Introduction
Hypertrophic scar (HTS) is a fibrotic skin disorder that is marked by exces-
sive inflammation and extracellular matrix deposition in response to cutaneous 
traumatic injuries such as burns, lacerations, incisions, and abrasions. Additional 
fibrotic skin disorders such as keloid scars are often thought of as being the same 
pathophysiology existing along a continuum of severity with HTS, and hence are 
often studied as one scar type, despite their varied etiology. HTS is one possible 
outcome of wound healing and has various risk factors, available treatments, and 
treatment effectiveness. Research at the basic, translational, and clinical levels are in 
their infancy compared to fibrotic diseases in other organ systems and compared to 
the study of keloids. This chapter will review current in vitro and in vivo modeling, 
and highlight research needs to address gaps in the study of HTS.
The following topics will be discussed in the chapter:
Modeling of HTS




ii. Limitations to these models
iii. Suggestions for topics of future research
b. Translational Science Research
i. Seminal findings
ii. Limitations to these models
iii. Suggestions for topics of future research
c. Clinical Research
i. Seminal findings
ii. Limitations to these models
iii. Suggestions for topics of future research
2 Basic science research
2.1 Seminal findings
Hypertrophic scar (HTS) can be defined through its hallmark clinical, histo-
logic, cellular, and molecular features. Each of these categories are intertwined and 
contribute to the complex nature of HTS (Figure 1). HTS has been examined in the 
laboratory in studies of basic science for decades, and these findings have led to a 
number of discoveries about the features of HTS as described below. Despite this 
plethora of findings, there are some limitations to current knowledge and plentiful 
area for future research. HTS and keloid scar are often grouped together into one 
scar phenotype, and research focused on keloid scar is often thought to be appli-
cable to HTS as well. Despite the similarities in these two fibrotic skin phenotypes, 
HTSs exhibit distinct histologic, cellular, and molecular features from keloids. The 
focus of this chapter is on HTS and not keloids, as the comparison of these two scar 
types would warrant its own review.
2.1.1 Histologic features
At a structural histologic level, there are several features of HTS including 
increased epidermal thickness, greater number of epidermal cell layers, and 
profound dermal thickness where HTS can reach up to several centimeters 
thick [1, 2]. HTS resulting from full thickness injuries lack dermal appendages 
such as hair follicles, eccrine glands, and apocrine glands. They also lack rete 
ridges and associated dermal papillae [1], and have increased cellularity and 
vascularity [3, 4]. Disorganized collagen with decreased inter-fibrillar spacing 
is a hallmark feature of HTS. Collagen changes its organization from the basket 
weave structure of normal skin to the nodular and whorl-like structure of HTS 
(Figure 2) [5–9].
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Mesenchymal-derived fibroblasts are often thought of as the main contributors 
to the development of HTS due to the fact that they are the primary cell type which 
makes up the dermis. Since the dermis of HTS is thickened, and therefore comprises 
the large majority of the HTS volume, fibroblasts are the most populous cell type 
within HTSs. Fibroblast proliferation is upregulated in HTS and apoptotic processes 
are halted [10]. Fibroblasts are the cell type which deposit extracellular matrix 
(ECM). In normal skin, the processes of synthesis/deposition and remodeling of 
ECM exist in a delicate balance. In HTS, this balance is skewed towards synthesis 
with greatly reduced remodeling, resulting in scars with extreme elevation of 
ECM-related proteins (such as collagen types-1 and 2, tenascin, fibronectin, and 
tissue inhibitors of matrix metalloproteinase (TIMPS)) and downregulation of 
remodeling proteins (such as a multitude of matrix metalloproteinases (MMPs)) 
[11–13]. Fibroblasts participate in paracrine signaling with all of the other types of 
cells within HTS, and their production of proteins related to HTS is often regulated 
by these cells.
There is heterogeneity within fibroblasts with cells obtained from the papillary 
dermis having a different molecular signature compared to those derived from the 
reticular dermis [14]. Deep dermal fibroblasts are activated when a certain critical 
depth of injury is obtained [15]. Dunkin et al. used a graduated scratch model in 
113 male and female healthy volunteers (ethnicity not reported) to determine this 
Figure 1. 




critical depth of 0.56 mm, or 33% of normal skin thickness at the hip where the 
wounds were created. HTS thickness was measured with high-frequency ultrasound 
scanning and showed that when wounds were made down into the deep dermis, 
HTS resulted, while injury to a superficial depth did not. The mechanistic reasoning 
behind this finding was elucidated when studying fibroblast cells derived from 5 
different skin layers. Skin was collected from reductive plastic surgery cases (with-
out demographic data reported), and a dermatome was used to section the skin into 
~0.5 mm pieces. This study showed that fibroblasts of the deep dermis have a simi-
lar molecular signature to HTS fibroblasts [16]. This signature included increased 
alpha smooth muscle actin (α-SMA)-positive cells that produced more collagen and 
less collagenase, increased versican, and decreased decorin. Hence, injury depth 
within the dermis is a critical driving factor for the development of HTS.
Hypertrophic scars demonstrate increased numbers of myofibroblasts, with 
greater quantities in scars of earlier phases of remodeling as compared to late-stage 
remodeling scars [8, 9]. Myofibroblasts contribute to the increased contractility of 
fibroblasts, and their differentiation occurs through a transforming growth factor 
beta (TGFß)-mediated signaling pathway [17]. Myofibroblasts (which express 
α-SMA in a similar manner to vascular smooth muscle cells) have increased rates 
of ECM synthesis. Further compounding ECM synthesis is the contribution of 
mechanical tension and its ability to contribute to the mechano-sensitive regulation 
Figure 2. 
Hematoxylin and &Eosin (H&E) showing histoarchitecture of HTS and skin. Regions of hyper- (top) and 
hypo (middle)-pigmentation share many of the hallmark characteristics of HTS compared to normal skin 
(bottom). Hyper- and hypo-pigmented scar and normal skin FFPE biopsies were stained with H&E. Scale 
bar= 500 μm at 1.25X (A) 100 μm at 5X (B) 50 μm at 10X (C) and 20 μm at 40X (D). Brackets indicate 
thickness (A) Circle indicates collagen organization (B) Arrows indicate rete ridges (C).
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of differentiation processes of fibroblasts to myofibroblasts [18, 19]. This is why 
wounds that heal under tension, such as across joints, are at great risk for the 
development of scar-related contracture [20]. Many studies aimed at the develop-
ment of potential treatments for HTS are intertwined with either the suppression of 
fibroblast to myofibroblast differentiation, or subsequent myofibroblast secretion 
of ECM [8, 21].
2.1.2.2 Keratinocytes
HTS keratinocytes are less well-studied in comparison to fibroblasts and in the 
past were thought to have a small role in HTS pathophysiology due to their small 
abundance compared to fibroblasts. However, they have been shown to be impor-
tant drivers of HTS due to paracrine signaling with fibroblasts and melanocytes 
[22]. Their appearance in the healing wound often signals the transition from 
the proliferative phase to the remodeling phase, and HTS develops most often in 
wounds where there was delayed re-epithelialization, implying that these cells have 
a critical role to play.
Keratinocytes are found in the epidermis, which is the outermost layer of the 
skin and comprises only a small portion of its overall structure, less than 10% of 
normal skin volume [23]. Despite its limited volume, it is a complex structure that 
is composed of four layers of ectoderm-derived stratified epithelial cells that form a 
continuum of differentiated keratinocytes (basal, spinous, granular, and cornified 
layers). Epidermal cells are replenished from epidermal stem cells that reside in 
the basal layer and originate from the bulge of the hair follicle. Once an epidermal 
stem cell is a resident of the basal layer of the epidermis, it is unipotent and can only 
differentiate to produce daughter keratinocyte cells [24]. The main function of the 
epidermis is to act as a barrier from the external environment, and hence protect 
from damage. Epidermal integrity is maintained by cell-cell and cell-matrix con-
nections made by desmosomes, adherens junctions, hemidesmosomes, and other 
structures comprised of a variety of integrins, glycoproteins, and proteoglycans 
[24]. Epidermal integrity is important for the maintenance of skin homeostasis, and 
yet damage can occur, especially during wounding or burn injury, due to bacteria, 
fungi, viruses, ultraviolet (UV) radiation, heat, or chemical exposure. The structure 
of the epidermis in normal skin is such that the basal layer of keratinocytes forms 
rete ridges in a predictable pattern which contribute to its attachment integrity.
It is known that keratinocyte-fibroblast (K-F) crosstalk is important during 
normal wound healing, and that keratinocytes can promote the development of 
fibroblast fibrotic processes. In an in-situ hybridization and immunohistochemical 
study of 22 Caucasian patients that had HTS resulting from partial thickness burns, 
expression of TGFß-1, TGFß-2, TGFß-3, basic fibroblast growth factor (bFGF), 
and vascular endothelial growth factor (VEGF) were evaluated at 1-, 4-, and 
7-months post-burn [25]. Keratinocyte expression of all proteins was up-regulated 
at one month compared to normal site-matched skin from the same patients. At 
4 months, some protein expression had returned to normal, and at 7 months, all 
growth factors were as expressed in normal skin. This data shows that keratinocyte 
cells are highly dynamic post-burn, and their signaling with growth factors is likely 
to significantly affect fibroblast cell processes. In a tissue-engineered model of 3D 
skin cultures, when keratinocytes derived from normal skin were seeded onto HTS 
fibroblasts, dermal thickness decreased. Similarly, when HTS keratinocytes were 
seeded onto normal fibroblasts, increased dermal thickness was likewise observed. 
This increase in thickness was regulated by collagen, MMPs, and apoptotic-
related processes [26]. Another paper displayed the importance of K-F crosstalk 
when studying fetal keratinocytes of differing gestational ages and the effect of 
Wound Healing
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their co-culture with fibroblasts on pro-fibrotic proteins. The co-culture of HTS 
fibroblasts with fetal keratinocytes (fetuses are known to produce scarless healing 
phenotypes) decreased proliferation of fibroblasts and decreased expression of 
collagen-1, α-SMA, and fibronectin [27].
A number of different methods can be used when characterizing keratinocyte 
influence on fibroblast cells or vice versa. One simple method is growing each cell 
type in monoculture and collecting the conditioned media (CM) from these cul-
tures and exposing the other cell type to the CM. Co-culturing of the two cell types 
can also be accomplished, however, differences in the optimum media properties for 
the two different cell types complicate this technique. Trans-well assays can be used 
to bypass this difficulty. 3D skin equivalents (either manufactured or lab-grown) 
can be used for a more complex system, and finally, organotypic cultures are also 
useful in the study of K-F crosstalk [22].
It has been suggested that HTS has altered expression of a number of keratin pro-
teins and additional proteins related to proliferation and differentiation of keratino-
cytes. These alterations, which are contradictory in different reports, indicate a role 
for these processes in the pathophysiology of HTS development (Table 1) [2]. Keratin 
proteins make up a component of the cytoskeleton in the stratified epithelial cells of 
the skin epidermis [35]. They are an intermediate filament that are either classified as 
acidic (type I) or as neutral-basic (type II). Type I and type II keratins form het-
erodimers that interact with each other to contribute to mechanical resilience within 
keratinocytes. In addition, the basement membrane attachment proteins (such as 
collagen IV, laminin-5 and integrin ß4) of the epidermis to the dermis are known to 
be altered in HTS [2]. This alteration is evident in a lack of hemidesmosomes and 
focal adhesion proteins.
Lastly, keratinocytes are also critical as one component of the multicellular 
“epidermal melanin unit” [36]. They interact with melanocyte cells in the induction 
of constitutive pigmentation and acquired damage-associated pigmentation. Their 
response to thermal damage and secretion of protein signals to neighboring cells is 
altered in post-burn HTS as discussed below.
2.1.2.3 Melanocytes
Melanocytes are derived from the neural crest and ultimately reside in the skin, 
mucous membranes, and retinal pigmented epithelium [37]. Melanocytes distribute 
evenly along the dermal-epidermal junction and there is no difference in melano-
cyte cell number, size, or shape between light and dark skin [38]. There are, how-
ever, regional variations within individuals with the face and foreskin containing 
the largest number of melanocytes per area and the abdomen and lower extremities 
containing the fewest cells [36]. Melanocyte precursor cells, termed melanoblasts, 
reside in the hair bulb and can be mobilized upon injury to re-pigment healing skin. 
When dermal appendages are destroyed in full-thickness injuries, melanocytes 
repopulate healing wounds; however, the origin of these cells is not well studied and 
is currently unknown. Presumably, a pool of melanocytes migrates from the wound 
edges. It is also possible that blood-derived cells home to the wound bed, differenti-
ate, and form a second pool of melanocytes. Melanocytes are characterized by the 
presence of two or more dendritic processes [36]. They are in contact with many 
keratinocytes and are able to interact with these cells through the extension of 
dendrites into a network of epidermal cells. One melanocyte can interacts with up 
to 30 keratinocytes.
The melanocyte and the keratinocytes with which it interacts form the multicel-
lular “epidermal melanin unit” [36]. The two cell types work as a unit to determine 
the pigmentation phenotype of skin. Constitutive skin pigmentation is apparent 
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Protein Type Localization 
in epidermis 
of normal skin
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Basal layer and 
suprabasal 
layer
Interacts with K14. 
Anchored to desmosomes 
via desmoplakin and 
plakophilin-1.
No different from 
normal skin [28]. 
Present In all layers of 
HTS with an increased 





All layers Interacts with K16 or K17. 
Activation of follicular 
keratinocytes during 
wound healing. Associated 
with hyper-proliferation. 
Induced by skin injury 
[29].
Up-regulated in HTS vs. 
normal skin throughout 
all suprabasal layers 
with strong staining 
[28]. Low or absent 
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[1]. No different from 
normal skin [28]. More 
suprabasal staining 








Interacts with K5 No different from 
normal skin [2, 28]. 
Present In all layers of 
HTS with an increased 




Basal layer Interacts with K5 Present In all layers of 
HTS with an increased 




All layers Interacts with K6. 
Associated with hyper-
proliferation. Induced by 
skin injury [29].
Up-regulated in HTS vs. 
normal skin throughout 
all suprabasal layers [28, 
30, 31]. Low or absent 




All layers Interacts with K6. 
Associated with hyper-
proliferation and tumor 
growth [32].
Up-regulated in HTS 
vs. normal skin [28, 
30]. Low or absent 




and can be observed in people of different races where, at baseline, without 
response to damage, there are different levels of pigmentation in people with 
different genetic backgrounds [39]. The induction of pigmentation can also occur 
when keratinocytes regulate exposure to the outside environment by processing and 
secretion of damage-associated environmental signals. Melanocytes then receive 
these protein signals and respond by upregulating pigmentation machinery within 
the cell. When pigment is produced, melanocytes package it into melanosomes, 
transfer it back to keratinocytes along their dendritic processes, and keratinocytes 
house melanin where it is used in a variety of functions [39]. It is clear that pigmen-
tation develops due to an increased rate of melanogenesis, and not proliferation of 
melanocytes [36].
Keratinocytes and melanocytes form the basis of investigation when attempt-
ing to develop treatments for dyschromia in burn-related HTS. Most pigmentation 
disorders such as Hermansky-Pudlak Syndrome, Waardenburg Syndrome, Type I 
Occulocutaneous albinism (OCA), Piebaldim, and Temperature-Sensitive OCA are 
genetic in origin and are a result of mutations to genes involved in melanogenesis 
[40]. Because burn dyschromia is a result of trauma, and not genetics, it is possible 
that it can be treated and potentially reversed. The first suggested treatments were 
reported in the 1980s [41, 42]. Onur et al. used a technique whereby they employed 
dermabrasion in the hypopigmented HTS area to ablate the epidermis and grafted 
Protein Type Localization 
in epidermis 
of normal skin
Function Role in HTS
Keratin-19 Acidic 
(type I)
Basal layer Does not interact with a 
type II keratin. Marker 
of epidermal progenitor 
cells [2].
Not detectable in  
HTS [2].
Involucrin N/A Spinous and 
granular layers
Transglutaminase 
substrate protein. Is a 
precursor to cornification 
in keratinocytes
In normal skin, common 
staining in the granular 
layer, HTS showed 
increased spinous layers 
and some basal  
layers [1].
Loricin N/A Cornified 
layers




Filaggrin N/A Granular and 
cornified layers
Interacts with keratin 
proteins. Important for 
epidermal barrier function 
and homeostasis.
Normal expression [1]. 
Differential gradient 
density in HTS vs.  
NS [28].
Ki67 N/A Basal layer Proliferation marker In HTS, percent of 
positive cells in basal 
layer was the same as 
normal skin [1]. Ki67 
positive cells were 
increased in HTS from 
breast reduction surgery 
at 3 months compared to 
normotrophic scars [31]. 
Increased expression 
in suprabasal layers in 
HTS [34].
Table 1. 
Keratinocyte proliferation and differentiation proteins. Localization in normal skin, function, and role in HTS.
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this area with thin (0.2-0.3 mm) skin grafts. They were able to show “adequate 
repigmentation” in their case series of 18 patients. In 1991, investigators in the 
United States published a similar study where hypo-pigmented HTS area was also 
prepared using dermabrasion [43]. An “epidermal” sheet graft was then taken at a 
depth of 0.0006 inches (0.015 mm) using a dermatome. This method used a much 
thinner graft that contained only epidermis so as to limit donor site dyschromia. 
Eighty six percent of patients had a good result and 13% had an excellent result. The 
same group extended their findings in a 1996 publication of the same title where 
they added an additional 21 patients to their case series [44]. Their findings were 
similar and somewhat improved over their previous study. Similar studies contin-
ued to occur, one reported substituting dermabrasion with flash-scanned CO2 laser 
to prepare the HTS area for thin split-thickness grafting (STSG) [45]. The papers 
described above report outcomes for patients treated exclusively for hypopig-
mented HTS. As time went on, this technique was also used to treat hyperpigmenta-
tion [46, 47]. In 1996 [48] and 1997 [49], concise reviews were published in Burns 
and the Journal of Burn Care and Research, respectively. They summarized the 
limited treatment options for postburn dyspigmentation. They described thin STSG 
after dermabrasion as the only surgical technique that was available at the time. The 
only other treatments that were mentioned were medical tattooing and temporary 
makeup [50–53]. Even as late as 2016, a paper was published showing the results of a 
retrospective chart review of patients who underwent dermabrasion and thin STSG 
from 1997-2007 [54]. Today, in many centers around the country, many patients are 
told that their only option for treatment of dyschromia is to use makeup or tattoo-
ing. Thin STSG treatment has benefits as discussed above; however, complications 
can occur. Some patients have experienced hyperpigmentation of the grafted 
site and donor site after sun exposure and cyst formation beneath grafts [42]. In 
addition, in patients with large TBSA injuries, who have extremely limited areas of 
normally pigmented skin, this sort of surgical correction is not an option. Lastly, 
there are only a few surgeons in the United States who perform this operation.
With this literature in mind, it is clear that none of these treatment methods are 
based on mechanistic reasoning. They rely on the transfer of cells or tissues from 
unaffected areas of the body to the HTS site. They can also lead to pigmentation 
abnormalities at the donor sites. As such, over the past many years, our lab has 
sought to investigate the mechanism of action of HTS dyschromia to develop treat-
ments with a mechanistic basis that may be more efficacious, tissue sparing, and 
more widely applicable than prior methods.
Our group came upon the study of dyschromia while conducting a study on the 
effectiveness of pressure therapy in a Red Duroc pig model of HTS [55]. The scars 
for study also developed dyschromia with areas of hyper- and hypopigmentation. 
These scars closely resembled HTS that was observed in our patient population, and 
hence, samples were acquired for study. Grossly, the scars were hyperpigmented on 
the periphery with small islands of hyperpigmentation in the interior surrounded 
entirely by hypopigmentation. The inside of the scars were mostly hypopigmented. 
Unexpectedly and interestingly, due to the dogma that is currently reported in the 
literature, we discovered that melanocytes were present in equal amounts in regions 
of hyper- and hypo-pigmentation by immunofluorescent staining for a melanocyte 
marker, S100B [56]. This work also showed increases in staining for melanin by 
azure B and melanin activation proteins, alpha melanocyte stimulating hormone 
(α-MSH) and human melanoma black 45 (HMB45) in hyper- compared to hypo-
pigmented scar. We next sought to further confirm the presence of melanocytes in 
regions of differential pigmentation, as well as look more in depth into the canoni-
cal pigmentation signaling cascade [57]. Melanocyte presence was confirmed by 
multiple assays including primary culture of these cells. In addition, a number of 
Wound Healing
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target molecules were shown to be up-regulated at the mRNA and protein levels in 
hyper- vs. hypopigmented scar, including pro-opiomelanocortin (POMC), adreno-
corticotropin hormone (ACTH), stem cell factor (SCF), melanocortin 1 (MC1R), 
stem cell factor ligand (cKIT), tyrosinase (TYR), tyrosinase-related protein-1 
(TYRP1), and tyrosinase-related protein-2 (TYRP2) or dopachrome tautomerase 
(DCT). While this work was useful in elucidating the molecules of interest that are 
up-regulated in hyperpigmented scar, and downregulated in hypopigmented scar, 
a mechanistic reasoning behind the dysregulation in the first step in the pigmenta-
tion signaling cascade was not revealed in this work. Canonical signaling by a DNA 
damage and p53-associated pathway were ruled out, as these moieties were not dif-
ferentially regulated in different pigment phenotypes. In subsequent work, POMC 
was further investigated as a potential root cause of hyper- and hypopigmentation. 
Methylation of POMC’s promoter was studied; however, there were no differences 
to suggest that methylation is the cause of dyschromia [58]. In addition, we used 
full transcriptome microarray analysis to identify a number of pathways that were 
differentially regulated between the two pigmentation phenotypes. These pathways 
provided us with additional and future avenues of study for preventing and treat-
ing dyschromia [58]. Some of this work is summarized in Figure 3. These studies 
are currently underway in our laboratory, and include treating areas of hypopig-
mentation with pigmentation stimulators as reviewed in our recent paper [59]. A 
recent paper by Dutta et al. is one of the few other mechanistic papers investigating 
Figure 3. 
Burn injury can result in dyspigmented scar that contains regions of hyper- and hypo-pigmentation with 
melanocytes in equal numbers. Examples of hyper- and hypo-pigmented burn HTS from two different patients 
(A) Epidermal sheets were stained for melanocyte marker S100β by en face staining. S100β (red), DAPI (blue). 
Scale Bar= 50μm at 10X (left) or 10μm at 40X (right) (B) Cells from regions of hyper- or hypo-pigmentation 
were isolated and imaged using phase contrast at 40X (B) Melanocytes and dendrite were counted in each 
region of pigmentation (C) Patient photographs were collected under an IRB-approved protocol and shared 
with patient consent.
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hypopigmentation in burn patients [60]. This paper studied immunohistochemical 
staining for cytokeratin 5, MC1R, Ki67, loricrin, and TYRP1. They also showed that 
dendricity in melanocytes was altered in hypopigmented cells in cell culture. This is 
a valuable study of dyschromia in HTS, but also does not reveal a mechanistic cause 
of hypopigmentation as the work is mostly aimed at characterization. The study of 
HTS is still a relatively new area of research compared to some other organ systems 
where fibrosis has been studied extensively. Dyschromia in HTS is an even newer 
topic of study and should be a priority due to its psychosocial effects for patients 
with HTS.
2.1.2.4 Endothelial cells
Endothelial dysfunction is a newer topic of study in the setting of trauma [61], 
sepsis [62], and burn injury [63]. It is known to play a role in acute burns where 
circulating levels of a proteoglycan component of the glycocalyx which is shed upon 
injury, syndecan-1 (SDC-1), is up-regulated in a dose-dependent manner in rela-
tion to injury severity. The glycocalyx is a complex meshwork of proteoglycans that 
line the luminal surface of blood vessels [64]. Circulating SDC-1 levels measured by 
ELISA can predict mortality, and the amelioration of the shedding of the endothe-
lial glycocalyx is a topic of current research in illuminating best practices for burn 
shock resuscitation [65, 66]. Due to the link between acute burn care and the long-
term systemic effects of burn injury, it is hypothesized that endothelial dysfunction 
likewise plays a role in the development of HTS, and if it can be ameliorated, then 
HTS may be able to be prevented or treated.
One characteristic of HTS that provides evidence for this link is the erythema-
tous nature that can result in purple, red, or pink scars that tend to improve over 
time. This erythema results from hyper-vascularity from an increased presence 
of blood vessels within these scars [67, 68]. Laser doppler imaging has shown an 
increased microcirculation and perfusion in HTS compared to surrounding un-
burned skin [69]. This data is somewhat contradictory to reports that; although 
there is increased blood vessel presence, these vessels are often totally or partially 
occluded through unknown mechanisms.
HTS are sometimes thought of as benign tumors that are “fed” by this vas-
culature [70]. In comparison to fibroblasts and keratinocytes, endothelial cells 
in HTS are less well-studied [71]. They gained recognition when a link between 
hypertension and increased hypertrophic and keloid scar severity was reported 
[72]. Hypertension can directly affect vascular function and as such, endothelial 
dysfunction is thought to play a role in scar development.
Pressure therapy is thought to work in part by “starving” the scar by inducing 
hypoxia [4]. Multiple non-pressure-related studies that target VEGF or angiogenesis 
have been studied to alleviate scar [73–75]. One such drug is endostatin which is 
a potent endothelial cell proliferation inhibitor. Endostatin inhibits angiogenesis 
and has also been shown to have an effect on tumor growth and metastasis. Its 
effects have been studied in a rabbit ear model of HTS where it was injected intra-
lesionally [76]. Treatment with endostatin resulted in decreased scar elevation index, 
decreased thickness, decreased microvessel density, and changes to collagen orga-
nization. Interestingly, mechanistic studies have focused on the effect of endostatin 
treatment on fibroblasts, and not endothelial cells [77, 78]. In addition, it has been 
shown in keloid scar that not only epithelial to mesenchymal transition (EMT), but 
endothelial to mesenchymal transition (EndoMT) may play a role in scar develop-
ment [79]. Endothelial pericytes may undergo EndoMT to become myofibroblasts 





Fibrocyctes are a peripheral blood mononuclear cell population (PBMC) mak-
ing up 0.5% of total leukocytes. These cells home to tissues during wound repair 
and play a role in fibrosis [81]. They are termed as such due to their “fibroblast-
like” properties and spindle shape in adherent cell culture. They are an interesting 
cell type because prior to their discovery in 1994, it was thought that all of the cells 
that contribute to wound healing migrated from surrounding areas of un-injured 
epidermis or dermis; however, blood-borne cells are now known to be critical for 
wound healing as well. When these cells differentiate, they lose hematopoietic 
markers and gain mesenchymal markers such as collagen, vimentin, cluster of 
differentiation 34 (CD34), and α-SMA. These cells target wound sites during the 
initial stages of injury and contribute to the inflammatory phase of healing by 
secreting a distinct profile of cytokines and chemokines, hence chemo-attracting 
other inflammatory cells. In addition, fibrocytes are known to be involved in 
numerous fibrotic diseases such as pulmonary fibrosis, asthma, atherosclerosis, 
and renal fibrosis [82–84]. They are present in post-burn HTS [85] where they are 
known to contribute to the proliferative phase by secreting ECM and the remod-
eling phase by secreting MMPs. They also regulate fibroblast activity through 
signaling with TGFß-1 and connective tissue growth factor (CTGF) by increasing 
cell proliferation, and migration, and increasing α-SMA expression, hence increas-
ing the contractility of collagen [86]. Fibrocytes have been identified as circulating 
cells in burn patients with a dose-dependent response in the number of circulating 
cells with increasing injury severity [87] and in a model of HTS in Red Duroc pigs 
[88]. Fibrocytes are a potential cell type to focus on when developing targeted 
therapies for systemic or local treatments for HTS. Indeed, when patients with HTS 
were treated with interferon-alpha (IFN-α) 2b, which was shown to stop fibrocyte 
differentiation in a dose-dependent fashion, the number of fibrocytes in HTS 
tissues was reduced, and the activity of the remaining cells was likewise reduced 
[89]. There may also be additional blood-derived cells of importance in regulating 
HTS [90].
2.1.3 Molecular features
There are also several molecular hallmarks of HTS including upregulation of 
overall collagen [91] with shifts in the ratio of type I and type III collagens [11, 12] in 
superficial and deep dermis. This upregulation generally results in higher levels of 
type III collagen in HTS [12]. TGFβ1 [92], insulin-like growth factor 1 (IGF1) [93], 
CTGF [94], platelet-derived growth factor (PDGF) [95], biglycan, pleiotrophin 
[96], and versican [97] are all upregulated, while decorin [97], MMPs, IFN-α 2b 
[98], interferon-gamma, and nitric oxide are downregulated compared to normal, 
uninjured skin [96, 99–103].
The complexity of HTS development is not only in mRNA transcriptomes that 
code for proteins, but in non-coding RNAs such as micro-RNA (mi-RNA), circular 
RNAs, and other long-non-coding RNAs. mi-RNAs bind to mRNA and most often 
lead to their post-transcriptional degradation prior to protein coding. Hence, mi-
RNA can have a drastic effect on protein expression. In the last 6 years, a flood of 
papers describing the effect of a multitude on mi-RNAs on HTS fibroblasts have been 
published. Dahai and colleagues have led the way with their work on mi-RNAs 21 
[104], 130a [105], 155 [106], 192 [107], and 494 [108]. mi-RNA-21 is one of the most 
extensively studied with 3 papers claiming that aberrant mi-RNA expression has a 
role on the fibroproliferative effects of HTS fibroblasts [104, 109, 110]. Additional 
mi-RNAs 145 and 200b have also been studied by more than one group and have been 
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connected to TGFß and Smad2/3 signaling pathways [111, 112]. Numerous others mi-
RNAs have been studied such as mi-RNA 181b which regulates decorin production 
in fibroblasts [113], mi-RNA 22 which promotes fibroblast apoptosis [114], mi-143 
which targets CTGF [115], mi-185 and mi-29 which both regulate TGFß and colla-
gen-1 expression [116], and mi-137 which regulate pleiotrophin [117]. Circular RNA 
[118] and long-non-coding RNAs [119, 120] also seem to play a role in HTS.
2.2 Limitations to these models
2.2.1 Histologic
As shown above, a large number of studies use either freshly cut or formalin-
fixed paraffin embedded tissue sections to study HTS at the histologic level. In 
patients, longitudinal biopsy studies are uncommon, though possible. As such, 
biopsies represent a snapshot in time and not the dynamic nature of HTS remodel-
ing. Patients often have multiple hundreds of square centimeters worth of HTS. 
In addition, these areas of scar may look heterogeneous due to staged, variable 
acute burn interventions. Especially in large TBSA injuries, HTS phenotypes may 
differ regionally, and one small, often 3-mm tissue biopsy, is often not sufficient to 
display the heterogeneity (of color, thickness, elasticity) of scar within a particular 
patient.
2.2.2 Cellular
The co-culturing of keratinocyte and fibroblast cells is far more developed in the 
study of keloid scar compared to HTS where there are only a few papers which utilize 
these techniques [121, 122]. Due to the difficulty of obtaining HTS tissue from which 
to derive cells, and the lack of a universally agreed upon animal model to provide 
these cells, experiments attempting to understand HTS-related fibrotic processes 
often use skin cells from either immortalized lines (such as HaCat cells), or from 
normal skin donors from reductive plastic surgery cases [123]. These cells are inferior 
to using HTS-derived cells. Additionally, HTS resulting from cutaneous non-burn 
related trauma may have different mechanisms. Therefore, papers studying HTS 
from surgical incisions, such as in breast reduction surgery, may not apply to more 
severe HTS, such as that encountered post-burn injury [124]. Additionally, mela-
nocytes are often not incorporated into in vitro models of HTS, under-emphasizing 
the importance of their role as photo-protectors of keratinocytes. Endothelial cells 
likewise are under-utilized in in vitro modeling of HTS, and should be added when 
attempting to model the full complexity of HTS. Fibrocytes and other blood-derived 
cells should also play a role in in vitro modeling for a more complete picture.
2.2.3 Molecular
After deriving primary cell cultures from HTS lesions and culturing cells in 
vitro, these cells often lose their molecular phenotype and don’t secrete the same 
proteins as they do in vivo. With the addition of passaging of cells that further 
remove them from their in vivo environment, these cells become farther and farther 
from the pathology which researchers are attempting to study. Part of the loss of 
molecular signatures in vitro is most likely due to the paracrine signaling from a 
multitude of cell types that contribute to severe scar phenotypes. Non-coding RNA 
findings are very new, and should be validated and studied in the future and treat-
ments related to these findings should be developed. Of note, all of these studies 
examine non-coding RNAs in fibroblast cells only.
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2.3 Suggestions for topics of future research
2.3.1 Histologic
In studies utilizing patient tissue biopsies, time post-burn and post re-
epithelialization, prior scar treatments, and demographic data including race 
and ethnicity should be judiciously reported. A large number of current studies 
report on Caucasian and Chinese populations, and future work should emphasize 
additional Asian, African, African American, Indigenous, and Hispanic patient 
populations. When one race or ethnicity makes up the large majority of samples, 
the title of the work should clearly indicate as such so as not to assert that all 
HTS contain these features. Blood collection should also be incorporated into 
prospectively-designed trials to evaluate the systemic responses to treatments or 
the natural systemic state that may contribute to HTS pathophysiology. Often, 
tissue biopsies are collected without companion blood samples. Details related 
to body location, and acute burn treatment of the particular biopsy site is like-
wise important for nuanced study of HTS at the histologic level. Longitudinal 
biopsies of scar can be performed in patients; however, large-scale studies should 
be reserved for animal modeling, and hint at the importance of both bench-to-
bedside research, and bedside-(back)to-bench research.
2.3.2 Cellular
It is as yet unclear what is the best model for studying HTS in vitro, though it is 
clear from the described studies above that using cells in monoculture is the most 
commonly used method. In addition, these cultures are often carried out in 2D. 
While using these simplified techniques may be useful for some research questions, 
it is important not to over-simplify scar modeling. By utilizing co-culture models 
of multiple cell types, these in vitro systems become more sophisticated and more 
similar to the in vivo environment. An example of a co-culture system that should be 
developed is endothelial cells with fibroblasts. The contribution of endothelial cells 
to HTS development is an area ripe for study. A method for isolating and culturing 
dermal microvascular endothelial cells has been published, and reports a relatively 
simple antibody-based cell sorting method that could be easily incorporated into cell 
isolation protocols from HTS tissue samples derived from patients or animals [125]. In 
addition, 3D cell cultures can be used to more closely mimic the organization of skin 
as a tissue structure. Such “scar in a jar” models are likely to be useful moving forward 
[126]. It has also been suggested that media components may be altered to create a 
pseudo “crowded” environment in culture. Crowders such as ficolls and dextrans of 
differing molecular weights are meant to take up a fractional volume of the media to 
mimic fibrosis where ECM crowds cells in vivo. Such techniques, termed macromolec-
ular crowding, should be incorporated into in vitro models in future work [127, 128].
2.3.3 Molecular
Future work should examine additional cell types when studying non-coding 
RNAs. The transcriptional profile of messenger RNA seems no longer adequate 
to explain the complexity of HTS. Non-coding RNAs should be incorporated into 
studies at the molecular level. As the scientific community progresses towards more 
sophisticated assaying capability in additional molecular components of the cells, 
these should all be likewise incorporated into our models. One such example is 
the discovery in 2020 of a novel tRNA-derived small RNA that plays a role in HTS 
fibrosis [129].
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Non-coding RNAs are an example of a mechanism that could be studied in 
samples or cells of dyschromic HTS lesions. The molecular and cellular mechanisms 
behind the development of dyschromia have not yet been elucidated, and may be 
related to epigenetic pathways such as non-coding RNAs. The reasoning behind 
this hypothesis is due to the fact that dyschromia often persists over many years, 
and does not improve over time like many other scar symptoms. This phenomenon 
seems to hint that there are epigenetic modifications that contribute to its long-last-
ing nature. In addition, when moving from in vivo to in vitro systems, dyschromia 
persists in cells, further providing evidence that epigenetic mechanisms may be at 
play. There are a multitude of areas that could be studied in relation to dyschromia 
including global or gene-specific methylation of melanogenesis or keratinocyte-
secreted proteins, acetylation patterns, or histone modifications. In addition, an 
interesting phenomenon is that HTS dyschromia does not improve over time even 
with treatment of scars that improve additional symptoms such as scar thickness 
or pruritis. The link between fibroblasts and melanocytes are an interesting area of 
future study due to the fact that treatments targeting the dermal cells do not seem to 
have an effect on melanocytes. HTS dyschromia is one area of research that should 
be prioritized due to its importance to patient populations for whom dyschromia is 
a factor in their psychosocial health.
3. Translational science research
3.1 Seminal findings
3.1.1 Patient samples and the need for animal models
Patient samples and patient-derived cells are often used to study HTS at the 
translational level. While these techniques can be useful, longitudinal and large-
scale studies likely need to occur in animal models. There is no perfect animal 
model for the study of HTS [130, 131]. Murine species are not acceptable models 
because of the “loose-skinned” nature of these animals (Figure 4) [132]. They also 
have a panniculus carnosus which allows them to heal by contraction instead of 
by granulation tissue deposition and re-epithelialization. As such, murine species 
do not form HTS and are not an acceptable model. Non-animal models for wound 
healing and scar formation have also been suggested [133]. These models include in 
vitro models utilizing co-cultures of HTS-derived cells and organotypic culturing 
of biopsies of HTS. Ex vivo models utilizing excised human skin have also been pro-
posed. While these models are useful for certain research questions, the drawback 
of not having the full in vivo system is clear.
A number of animal models for HTS have been proposed, including nude 
mouse models of xenografted human normal skin or HTS, the rabbit ear model, the 
Yorkshire pig model, and the red Duroc pig model. Each of the models has its own 
inherent pros and cons and each can be useful depending on the details of the spe-
cific research question. In addition, some papers claim that there is no universally 
accepted animal model for HTS, and hence, there is discord in the literature about 
methods for HTS creation even within the same species.
3.1.2 Nude mouse models
Nude mouse models of xenografted normal human skin have been used to 
create human-like HTS [134–136]. Although the skin was normal, and not HTS 
when it was xenografted, the skin forms scar that has many of the morphologic 
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and histologic criteria of HTS. Additional models have been developed over time 
where the normal skin is “scratched” to create a wound in the skin that then forms 
additional HTS [137].
3.1.3 Rabbit ear
The rabbit ear model likewise has its pros and cons [138]. It involves creat-
ing a small (6-8 mm) full thickness excisional wound in the ear of New Zealand 
white rabbits. Because the rabbit ear does not contain a panniculus carnosus, the 
small wounds heal with fibrosis and share some of the hallmarks of HTS including 
increased thickness, vascularity, and cellularity. In most papers, 6-8 scars are created 
on each ear and treatments are applied to each HTS as individual biologic replicates.
3.1.4 Yorkshire pig
The Yorkshire pig model is useful for modeling HTS similar in phenotype to 
scars from patients with baseline light skin pigmentation [139–144]. These scars 
are often described as “port-wine” scars due to their erythematous nature due to 
increased vascularity. They have increased thickness compared to normal skin 
(~2X), decreased tensile strength, different collagen architecture, increased 
vascularity, increased TGFβ expression, increased presence of myofibroblasts, and 
decreased presence of rete ridges [140]. This model is useful for certain research 
questions related to the prevention and treatment of scars that are present in 
patients with light skin pigmentation.
Figure 4. 
Porcine skin most closely resembles human skin compared to rat and mouse skin. Epidermal and dermal 
thickness are similar and dermal appendages are present in similar densities. All animal work was conducted 
under IACUC-approved protocols.
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3.1.5 Duroc pig
In the 1970s, Silverstein et al. reported HTS development in red Duroc pigs after 
deep dermal wounding. They never published their model however, and it was 
not widely adapted. In 2003, Zhu et al. published an examination of a number of 
wound thicknesses and the resulting HTS that developed under different conditions 
in female red Duroc pigs [145]. They found that the creation of 8 cm by 8 cm (3.1 
inches by 3.1 inches) deep partial thickness or full thickness wounds with a total 
dermatome setting of 0.06” to 0.09” led to the development of HTS that was thick, 
hypercontracted, and hyper-pigmented. In addition, there was disorganized colla-
gen structure and many of the genes of interest known to be dysregulated in human 
HTS were appropriately dysregulated. The same group went on to publish a number 
of papers demonstrating the clinical, histologic, and molecular similarities of Duroc 
pig HTS to human HTS [68, 146–149]. Around the same time period, another group 
published similar findings in Duroc pigs [150, 151]. Gallant et al. used females or 
castrated males and created 2 cm by 2 cm (0.8 inches by 0.8 inches) full thickness 
wounds using a scalpel to remove the full thickness skin down to subcutaneous fat. 
Multiple small wounds were created in 2 rows of 10 wounds per flank. These HTSs 
ultimately progressed to become hyper-pigmented at day 70.
It was around the time of the publication of these novel Duroc pig HTS model 
papers that our lab became focused on developing a similar model for HTS. We 
began modeling with Duroc pigs to study partial thickness wounds in relation to 
donor site healing dynamics [152] and wound healing accelerating agents [153]. 
These wounds were created at a total dermatome setting of 0.06” and were 7.62 
cm x 7.62 cm (3 inches x 3 inches) in size. These partial thickness wounds healed 
without the thick fibroproliferative nature of HTS; however, some hyper-pig-
mentation was observed. We then continued our investigation into the creation 
of full thickness wounds to generate HTS (Figure 5). During this project, where 
the primary goal was to study pressure delivery, HTSs were generated by full 
thickness wounding with a total dermatome setting of 0.09” and size of 10.16 cm 
by 10.16 cm (4 inches by 4 inches) [88, 154–158]. Throughout the course of  
this work, dyschromia, with regions of hyper- and hypo-pigmentation, was 
apparent [56].
3.2 Limitations to these models
3.2.1 Patient samples
Studying patient samples is most likely the best recapitulation of the disease 
process; however, this strategy has the drawback that it is a snapshot in time. These 
samples do not provide any information as to the natural history of HTS formation, 
as they must be taken after a scar is already formed. Additionally, HTS samples 
from patients are most likely at the severe end of the spectrum because the samples 
can most often only be collected during surgical HTS excisions.
3.2.2 Nude mice
While these models are useful, and they have shown retention of the HTS and 
pigmentation phenotype even 1-year post-xenografting, the etiology of HTS is 
not the same as the etiology of full thickness wounding or burn injury. Lastly, this 
model relies on the availability of large amounts of normal human skin, a resource 




The model is affordable and has been used successfully to investigate a number 
of drug treatments; however, not many of these have made the leap to clinical 
treatments. This model does not acknowledge the potential local-regional effects of 
drug treatments on HTSs. Lastly, the overall skin structure of the rabbit ear is not 
similar to human skin because it sits upon a bed of avascular cartilage [138]. The 
model’s main limitation is the size of the scars for study, which are small. In addi-
tion, dyschromia is not evident in these scars.
3.2.4 Yorkshire pig
In Yorkshire models of HTS, the resultant scars are not as thick as human HTS 
and they are not raised above the surrounding tissue. This phenomenon is most 
likely because fibroblasts derived from Yorkshire skin have an inherently less fibro-
proliferative phenotype compared to Duroc pig fibroblasts [159]. Fibroproliferation 
was demonstrated by Duroc pig fibroblasts to show increased actin stress fiber 
formation and adhesion complexes, decreased cell migration, increased cell con-
traction, and differential expression of HTS-related genes of interest (α-SMA, type 
I collagen, decorin, and TGFβ) compared to Yorkshire pig fibroblasts. Lastly, the 
Figure 5. 
Our lab’s model of full-thickness excisional wounding to generate HTS in Red Duroc pigs. Baseline, un-injured 
Duroc skin has a red-brown phenotype. Full-thickness excisional wounds created by dermatome down to 
subcutaneous fat with no residual dermal appendages are created. Dyschromic, rigid, thick, HTS is generated 
112 days post-wounding. This scar is thick compared to normal skin.
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Yorkshire pig model for HTS is insufficient for certain research questions because 
there is no melanin-related dyschromia in this model.
3.2.5 Duroc pig
From 2012, when our lab began with this model, to present day, multiple labs 
have adopted the Duroc pig as a model for HTS formation. There is still no universal 
method for the creation of scars as some labs use excisional techniques at differ-
ent depths and with different instruments [160–162], burn techniques [163–166], 
and burn, excision, and auto-grafting techniques [167–170]. Many scar models 
use small wound sizes that are not a significant wound burden on the animal. The 
full thickness nature of the injuries created in our model, as well as the large size, 
helps to closely mimic the HTS features that were observed in patients during the 
parallel timeline that experiments were taking place. Finally, the use of pigs, and 
specifically Duroc pigs, which are not a common animal breed, is expensive due to 
housing considerations and operative room time. This fact is often a limiting factor 
for their use.
3.3 Suggestions for topics of future research
3.3.1 Patient samples
Basic and translational scientists should work closely with physician-scientists to 
ensure that the questions they are trying to answer in basic or translational models 
are important for patients. As a community, we need to determine how improve-
ments can be made to the implementation of translational work to the bedside. Too 
often, prevention or treatment techniques for HTS are developed in animal models 
only to stall out and never reach patient care settings despite their effectiveness.
3.3.2 All models
Often times, basic and translational science research lag behind current clinical 
findings such that patients receive treatments based on anecdotal evidence. This 
was the situation when fractional CO2 ablative lasers were first used to treat HTS 
in patients. The cellular and molecular mechanisms behind this treatment had 
not been revealed even though patients continued to receive and benefit from this 
treatment. When questions arise in the clinical setting, it is useful to return back 
to the bench in order to test hypotheses. It is difficult, expensive, requires a large 
number of patients, and extensive regulatory review processes to conduct a clinical 
trial with patients. As an alternative, hypotheses that are early on in their develop-
ment would benefit to be studied in animal models. The optimization of prevention 
or treatment effectiveness by testing different application techniques (systemic, 
injections, topical, laser channel drug delivery), dosing, and time-courses can all 
be studied in animals prior to testing in patients. Safety profiles are also critical to 
complete in translational work.
3.3.3 Pig models
Researchers using pig models for studying HTS debate which species produces 
the best model for study. Even when “definitive” papers are published declaring 
a model to be the most similar to human HTS, debate still follows. This was the 
case for the development of the Red Duroc pig model. Although the authors of 
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the multiple papers characterizing this model never claimed that it was a perfect 
animal model, its development was still novel and important. Even so, researchers 
have been altering and optimizing this model ever since and rarely, if ever, use their 
original experimental methods to create HTS. The Duroc pig model, even in our 
laboratory, is admittedly not perfect. The resultant scars are not as raised above the 
surrounding skin compared to human scar. As such, they never truly become as 
thick as the most severe human scars. In addition, it is difficult to create a homog-
enous scar phenotype, specifically with regards to dyschromia, as the development 
of this symptom is still unclear in its etiology. In addition, full-thickness burning 
without excision and grafting, or the use of excisional wounding alone without 
burn is a controversial topic. Some researchers believe that including the burn, only 
to excise it after 2 days, may not be a judicious use of resources, and sometimes 
exclude the burn if the goal is to develop HTS for study. Some researchers empha-
size the importance of including burn if the research question is mechanistic in 
nature. Models which incorporate healing by secondary intention or delayed exci-
sion and grafting more closely mimic burn-wound healing in low-income countries 
or in patients with very large TBSA injuries, two situations which are associated 
with some of the most severe HTS. In high income countries, early excision and 
autografting of full thickness or deep partial thickness burns is more common and 
accessible due to available resources. There are a few models that comprehensively 
include burn, excision, and autografting techniques in pigs, however, they often 
result in nicely healed wounds without extensive HTS. Patient factors that contrib-
ute to severe scarring even at autograft sites are not fully recapitulated in animal 
models. In addition, it is experimentally difficult to incorporate scarring across 
joints in animals. Frequently, wounds in pig models are situated on the flank, a site 
relatively shielded from tension with normal movement. Tension in healing wounds 
is an important topic for future study. Lastly, the use of pigs for scar research is 
extremely expensive. Low numbers of replicates can be incorporated onto each pig 
if systemic and local-regional contributions are being taken into account. The use of 
nude mouse models of scar or humanized mouse models, are thus a very intriguing 
concept. These models, which are substantially less expensive, will allow for large 
numbers of experimental replicates without systemic confounders. While current 
nude mouse models are useful, we should continue to report new techniques to 




4.1.1 The development of hypertrophic scar
Incisional wound healing is well-described and typically marked by minimal 
inflammation and non-pathologic scar [171, 172]. Delayed wound closure or that 
which heals by secondary intention or contraction is, by contrast, marked by 
prolonged inflammatory events followed in many cases by degrees of fibrosis and 
ultimately HTS. Severity of scar after wounding of the skin is related to wound size, 
depth, anatomical location, tension, nature of injury, infection, environmental 
factors, and genetic predisposition [173]. HTSs have been succinctly summarized 
as an over-abundant synthesis of collagen and under-abundant or absent remodel-
ing process. Despite this oversimplification, over the past several decades, there 
has been a large amount of research investigating the mechanism behind HTS 
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Figure 6. 
HTS can result from a variety of injuries. HTS can result from wounds that are not treated with autologous 
skin grafting (A) treated with mSTSG (B) from donor sites (C). One of the main symptoms of HTS that can 




formation [100, 174]. The known severe inflammatory response that occurs after 
thermal injury has been suggested as an explanation for the greater incidence of 
HTS after burn injury than after other sources of injury [175]. A longer time to 
healing is associated with a greater risk of HTS, and in the case of burn injury, the 
most important prognostic indicators for HTS are the depth of original burn and 
corresponding time to wound closure [176, 177]. HTS can occur in wounds that 
were allowed to heal without mSTSG (Figure 6A), in wounds treated with mSTSG 
(Figure 6B), and in healed donor sites (Figure 6C) [178, 179]. Reliably, open 
wounds and full thickness burns that do not receive timely interventions to facili-
tate soft tissue coverage result in thickened, inflexible, pathologic HTS, though even 
wounds that do receive timely intervention may be susceptible.
Frequently, two to three weeks is used as a rule of thumb for time to wound 
closure for minimization of the development of HTS, with an understanding that 
a shorter time to healing is typically associated with a decrease in scar severity. It 
follows then that impairments to expedient wound healing are likely to contribute 
to the likelihood of HTS. Such impairments may include nutritional deficiencies 
(vitamin C, vitamin D, protein-calorie malnutrition), vasculopathy (peripheral 
arterial disease, diabetic microcirculatory disfunction, venous insufficiency), 
cigarette smoking, and infection among others [172]. It still occurs that patients 
with otherwise similar injury qualities and wound healing contributors develop 
varied severities of HTS, and this finding has been inadequately explained. 
There is evidence that certain genetic pre-dispositions put patients at risk for the 
development of HTS [180, 181]. Accordingly, patients of Asian, Hispanic, African 
American, or African descent are more likely to develop scar and exhibit increased 
scar severity [177, 181, 182].
The natural history of HTS generally predicts that a scar will be hypervascular, 
hypersensitive, dyschromic, and pruritic for the first few years after injury, typically 
accompanied by thickness and impaired flexibility. Some improvement in these 
qualities is to be expected over the following years, and some authors even suggest 
that HTS will revert to flat, asymptomatic scar [172]. In our own practice, however, 
patients with burn-related HTS may present decades after injury with persistent 
pain, itch, thickness, and range of motion limitations at sites of scar, suggesting that 
in at least some patients, these never truly resolve without targeted intervention. 
Due to the highly pervasive nature of HTS, and the fact that large total body surface 
area burn injuries are now survivable, a shift in focus has put HTS rehabilitation and 
recovery at the forefront of current research efforts by burn providers.
4.1.2 The evaluation of hypertrophic scar
Currently available scar evaluation tools include both subjective scales and 
objective mechanisms. In 2012, Tyack, et al. published a systematic review of 
eighteen different burn scar rating scales used in clinical and research settings 
[183]. The Vancouver Scar Scale (VSS) is most frequently cited and is a widely used, 
clinician-reported scale composed of four metrics: vascularity, pigmentation, pli-
ability, and height. Scars with lower scores are characterized as “better” and more 
similar to normal skin [183, 184]. A number of modifications to the VSS have been 
made and applied in differing circumstances [183].
The Patient and Observer Scar Assessment Scale (POSAS) is also commonly 
used and is similar in its evaluation of the above metrics, but it provides additional 
levels of evaluation that quantify a patient’s experience of pain and itch [185–191]. 
This scale was originally created for the evaluation of linear scars, but has been used 
in the evaluation of a much wider variety of scars [190]. Some criticism of the use 
of this scale in the context of HTS is that patients are asked to compare an area of 
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scar to that of normal skin. This question prompts dissatisfying responses despite 
clinical interventions and improvements, as we know that there is no currently 
available method by which to convert HTS back to normal skin.
Other scar assessment scales noted in a 2010 systematic review by Brusselaers, 
et al. include the Seattle Scar Scale, Manchester Scar Scale, Hamilton Scar Scale, 
Inventory of Potential Reconstructive Needs, and the Stoney Brook Scar Evaluation 
[191]. The four original components of the VSS are commonly evaluated in most 
scar rating scales, but additional parameters beyond these do not share clear 
consensus in systematic reviews [183, 191].
A wide variety of objective scar measures have been developed and used to some 
degree, though without consistent or widespread adoption. A scar’s height may 
be simply measured with a standard ruler, though this is an incomplete technique 
because it represents only scar thickness above the level of the surrounding skin and 
does not take into account variability in height within a given scar [192]. Planimetry 
improves upon this method by measuring the surface area of a scar, accounting for 
its variations in height, but still does not account for scar area deep to the visible 
surface [193]. Various three-dimensional imaging techniques are available, but 
these are not widely used due to their high costs [194, 195]. High frequency ultra-
sound may be used to more completely gauge scar thickness and is gaining some 
popularity for evaluation of the effects of HTS interventions [192, 196]. Elasticity 
or stiffness of scar can be measured by various methods including suction, pres-
sure, torsion, and extension, all typically with a non-invasive probe [197]. Acoustic 
methods for scar assessment use sound waves to detect heterogeneity in scar tissue 
[198]. Transcutaneous oxygen tension can be measured with skin electrodes, as 
HTS have been noted to have a lower partial pressure of oxygen than healthy skin, 
however this technique has not been described frequently in the literature over the 
past 3 decades [199, 200]. Trans-epidermal water loss estimates the barrier func-
tion of scar related to the moisture content of skin [201]. Range of motion can be 
measured with a standard goniometer to estimate disability of movement due to 
scars in proximity to joints [197].
4.1.3 The treatment of hypertrophic scar
There are currently limited treatment options for HTS, and as such, preven-
tion based on appropriate acute management of cutaneous injury is of paramount 
importance. When HTS develops despite good acute management, there are several 
treatment strategies that are employed. In decades past the main approach to the 
treatment of HTS was to “wait and see” and allow HTSs to regress over a period of 
years. While HTSs are known to get better over time, in contrast to their counter 
parts, keloid scars, which remain stagnant or worsen over time, HTSs almost 
never regress back to the structure or functionality of normal skin. This “wait and 
see” strategy often leaves patients with moribund scars that would benefit from 
additional treatments. Additionally, were interventions offered earlier on, patients 
have the potential to prevent multiple years of suffering. Early prevention strate-
gies using our current multi-modal approach are critical to preventing severe scar. 
Common, longstanding treatments include compression, massage and stretch, 
silicone gel and sheeting, drug injection, and surgical tissue rearrangement, all of 
which have a role in prevention and treatment of HTS symptoms, but have draw-
backs and can result in suboptimal outcomes when used in isolation [202–206].
Compression therapy is a widely used technique that has been considered 
standard of care for burn-related HTS for over 50 years. It is most commonly 
provided via elastic compression garments or plastic molded face masks for the first 
year following a burn injury. These are worn 23 hours per day and have been shown 
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to improve scar height and erythema over time when custom fitted to a pressure 
of 20-30 mmHg [207]. Acceptance of this treatment modality is based mainly on 
anecdotal experience as the mechanism of action is not fully understood [208]. In a 
recent evidenced-based practice review by Sharp et al., pressure therapy is recom-
mended as a successful scar treatment which results in improved aesthetic outcomes 
by reducing scar height and erythema [203, 208–212]. Patient compliance and dura-
tion of treatment are important factors in the success of pressure therapy [213]. Our 
lab has studied the effect of compression on HTS extensively [55, 214] and revealed 
its mechanism of action to be primarily related to the induction of changes in colla-
gen levels and types [157], elastin levels [156], and MMP levels [154]. Additionally, 
we have demonstrated that pressure therapy not only acts through mechanical 
forces, but induces changes in the HTS at the cellular and transcriptomic level that 
induce remodeling [155]. Despite pressure therapy’s success in treating some symp-
toms of scar, patients often have sub-optimal functional and cosmetic outcomes 
even after treatment, which lead them to seek additional care.
Massage and stretch are routinely suggested for treatment of HTS despite mixed 
and limited evidence of their effectiveness [175, 215–218]. These techniques have 
minimal cost and can in many instances be self-administered with little to no risk, 
thus their use persists in the absence of convincing studies. A 2006 Cochrane review 
of silicone-based interventions for the prevention or treatment of HTS determined 
that there was only poor quality weak evidence of its benefit [219]. Since that time, 
more promising evidence for the benefit of silicone-based treatments have emerged. 
Proposed mechanisms of action include increased temperature, increased hydra-
tion, and bestowing a polarized charge to tissues, though none of these mechanisms 
have conclusively been shown [175]. It seems that the combination of silicone with 
compression therapy is advantageous compared to silicone or pressure therapy 
alone and provides benefits pertaining to pigmentation, vascularity, pliability, and 
itch [175, 220]. Intralesional injection of HTS may be with glucocorticoid (com-
monly triamcinolone, TAC) 5-fluorouracil (5-FU), or verapamil. Suggested mecha-
nisms of action are suppression of the inflammatory response with TAC injection, 
reduction in the synthesis of ECM with verapamil injection, and inhibition of cell 
growth and induction of apoptosis with 5-FU injection [175]. The combination of 
5-FU and TAC appears to have the greatest effect according to a recent systematic 
review [175, 221]. Surgical management of scar is a large topic in its own right and is 
not reviewed here; however, absent large scar excision with accompanied closure by 
grafts or flaps, zig-zag patterned incision, rearrangement, and suture approaches 
(z-plasty, w-plasty, and others) benefit linear HTS by a decrease in focal tension 
with accompanied histologic changes [222, 223].
Over the past 20 years, laser and light-based therapies have gained increasing 
popularity amongst clinicians who work to treat burn HTS [224–226]. Initially, 
the pulsed dye laser was most commonly used, and has now been supplemented 
in many centers by fractional ablative laser platforms [227–230]. Fractional pho-
tothermolysis was first described in 2004 [231]. This variation of laser treatment 
is based on the concept of creating multiple individual microscopic channels in a 
targeted treatment area. The laser causes small, limited zones of photothermolysis 
within tissue due to focal energy deposition at a wavelength absorbed by tissue 
water [232, 233]. The microinjuries are small enough that skin barrier function is 
preserved and healing is achieved without new scar formation [231, 234]. In addi-
tion to clinical improvements, histological and molecular evaluations of treated 
HTS reveal changes in inflammatory responses, matrix remodeling, and overall 
scar structure [168, 235]. This technology was initially created with the goal of 
aesthetic treatment of photo-damaged skin, but has shown increasing applicability 
for the treatment of various traumatic scars over the past decade [236].
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4.2 Limitations to current clinical knowledge
4.2.1 The development of hypertrophic scar
Patients of similar age, health, and nutritional statuses with injury types and 
clinical managements in common may still develop different scar phenotypes. 
A trend toward worsened scar hypertrophy in skin of color has been observed 
[182, 237]. To further elucidate these basic genetic predispositions, various 
investigators have attempted to focus on genotypic variations associated with 
HTS. Carriers of some specific major histocompatibility complex alleles (HLA-
DRB1*15, HLA-DQA1*0104, DQB1*0501, and DQB1*0503) show a genetic suscep-
tibility to keloid disease, but these are not as clearly implicated in HTS [173]. The 
melanocortin 1 receptor single nucleotide polymorphism R163Q was associated 
with severe HTS in a study of 425 subjects in 2015 [182]. In 2016, the same group 
found that a missense variant of a mitogen-activated protein kinase pathway 
inhibitor PTPN5 was protective against HTS in a study of over 538 subjects 
[238]. Investigational studies such as that by Tsou, et al. have use cDNA microar-
ray analysis to suggest that greater than 100 genes are differentially expressed 
between HTS and normal skin or non-pathologic scar. Implicated genes appear to 
be involved in collagen expression, growth factors, and MMPs and their inhibi-
tors, however there was great variation between individual scars, and the total 
number of scars was small [239]. Given the expected high variability between 
individuals, large numbers of scars that will generate “big data” sets still need to 
be evaluated to discover reliable trends with respect to gene expression in HTS.
A less well-studied HTS feature is the dyspigmentation or dyschromia that 
occurs in the cells of the epidermis, namely the keratinocytes and melanocytes. In 
addition to the functional limitations of HTS, the aesthetic symptoms of HTS can 
also have severe psychosocial effects on patients which contribute to challenges 
with social reintegration and lead to decreased quality of life, and are, therefore, of 
importance to study [240–245]. In addition, dyspigmentation is difficult to predict, 
heterogeneous with regions of hyper- and hypo-pigmentation, can persist without 
improvement over time, and is pervasive amongst patients with baseline dark skin 
pigmentation [246].
4.2.2 The evaluation of hypertrophic scar
The various objective and subjective measures of hypertrophic scar have unique 
strengths and weaknesses [183, 191, 200]. The optimal combination of measures 
to evaluate scar severity and response to treatment has not been outlined. In a 2015 
evaluation of the VSS, there was no consensus amongst 130 burn care providers 
as to what value on the scale constituted clinically significant HTS [247]. Lee et al. 
have recently attempted to delineate an optimal global scar evaluation protocol with 
the combination of a modified VSS and a panel of objective scar measurement tools 
[247]. While not yet validated or accepted widely, the intent of the work is valuable 
and a collaborative effort to this end will benefit both clinicians and researchers 
working with HTS.
4.2.3 The treatment of hypertrophic scar
As previously described, many current clinical interventions to prevent and 
treat HTS are used based on clinical experience with variable evidence. Proposed 
mechanisms exist for the use of silicone, compression, intralesional injection, 
and local tissue rearrangement, though these have not been explicitly outlined 
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[175]. The current treatments described above have varied effectiveness for 
relieving symptoms of HTS such as thickness, pliability, and pain, but are inef-
fective for the treatment of dyschromia. In fact, most research into HTS focuses 
on methods of targeting dermal remodeling, and does not focus on the epidermis. 
This focus is due to the fact that HTSs are often characterized by fibroblast cells 
and ECM that make up the dermis [99, 159]. These cells are the general focus of 
most research because they contribute to the thick, non-pliable, and contracted 
symptoms of HTS [248].
A consensus statement on laser treatment of burn scars was created in 2014 
highlighting currently demonstrable benefits of fractional ablative CO2 (FCO2) 
laser scar revision (LSR). These include a small immediate increase in range 
of motion (ROM) as a result of photomechanical scar release, followed later by 
improvements in pliability, durability, texture, dyschromia, and further range of 
motion, all of which have been attributed to a collagen remodeling response [188]. 
Experience with FCO2 LSR at our institution reflects these improvements in the 
evaluation of patients with burn HTS. The improvement in HTS after treatment 
with FCO2 is well-documented [249, 250]. How and when these improvements 
occur has not been clearly defined. Existing studies frequently demonstrate changes 
in HTS in a bimodal fashion—only prior to and after multiple treatments in a course 
of LSR [225, 229, 230]. In practice, rarely does a patient undergo a single FCO2 treat-
ment for symptomatic HTS, however an adequate number of treatments, frequency 
of treatments, preferred settings, timing, and expected time course of outcomes is 
still undefined.
4.3 Suggestions for topics of future research
4.3.1 The development of hypertrophic scar
The incomplete understanding of genetic predisposition to scar is an area wide 
open for investigation. The patient-specific contributing factors leading to the 
development of HTS, as well as the degree to which a given individual responds 
to any clinical intervention, has not been elucidated with any practical clarity. If 
patient-specific information were to become available, targeted interventions for 
both the prevention and treatment of HTS could be developed for best outcomes. 
The work begun by Tsou, et al. as well as Sood, et al. could be continued, as the 
number of scar and skin samples needed to establish clear gene expression trends 
in HTS is overwhelming [182, 238, 239]. That said, banking results from skin and 
scar of varied patient ethnicities, ages, injury types, clinical interventions, and 
health backgrounds could yield enormous information pertaining to the preven-
tion, development, and treatment of HTS. Once a genetic blueprint associated 
with or protective from HTS is more clearly outlined, the interplay of a specific 
patient’s age, injury-specifics, and medical comorbidities will add further layers 
to the ability to develop targeted approaches to the prevention and treatment of 
severe HTS.
4.3.2 The evaluation of hypertrophic scar
Scar assessment tools have been evaluated largely in the context of burn HTS 
[200]. No clear standard exists and a clearly defined pathway to scar evaluation is 
yet to be determined. The standardization of these measures is needed in order to 
reliably evaluate the effectiveness of the clinical treatments for HTS. Many avail-
able tools are useful and promising; however, scales have not been established to 
define normal ranges nor expected values which represent clinically significant 
27
The Need for Basic, Translational, and Clinical Research in the Field of Hypertrophic Scars
DOI: http://dx.doi.org/10.5772/intechopen.96943
improvement. Likewise, devices have not been adopted similarly across multiple 
centers offering similar clinical managements. Work aimed at a standard set of 
metrics with accessible tools would benefit HTS-focused clinicians, researchers, 
and their patients. These metrics should incorporate patient-centered measures 
with a focus on symptoms affecting quality of life in the subjective realm; objec-
tively, goals include a standard method to quantify scar size, thickness, vascularity, 
pigment, patterning, and flexibility with reproducibility and accessibility across 
healthcare delivery systems.
4.3.3 The treatment of hypertrophic scar
Many of the approaches for treatment of HTS has come from anecdotal use and 
experience. Future study of HTS may include validating any of these techniques. In 
any study of therapies for HTS intervention or prevention, there exists the challenge 
of developing and incorporation of appropriate controls. There is some expected 
improvement and remodeling of scars over time even without interventions, but the 
degree to which these occur is varied amongst different people and even within the 
same person. A valuable approach to this issue has often been through the design 
of interpatient controls by randomizing multiple distinct scars in a single patient or 
through split-scar studies, comparing treated and untreated portions of the same 
scar [251–253]. Separate scar interpatient controls are unable to account for the vari-
ability of scar physiology based on patient genetics, lesion location, or differences in 
original wound depth. Large scale trials, potentially with the assistance of multiple-
center enrollment, would be most effective at minimizing these naturally-occurring 
confounding factors. In split-scar studies, the effect on an untreated portion of scar 
in direct proximity to a treated portion of scar is also not clear, and the systemic 
effect on areas untreated, however distant, deserves attention moving forward as 
various treatment approaches are studied.
Of course, the testing and validation of any scar treatment technique would 
require reliable, reproducible evaluation of treated and untreated HTS to speak to 
true efficacy. As noted above, current evaluation techniques carry wide potential, 
but have not been standardized in many cases with respect to normal ranges, multi-
institutional adoption, timing of use, and expected values for scars of different 
ages, injury types, and locations. Clearly defining a suggested set of evaluation 
metrics for scars would contribute to the field by allowing researchers and clinicians 
to communicate consistently when testing various scar prevention and treatment 
strategies moving forward.
Laser scar revision is the most promising development for the treatment of HTS 
in the past decade. Variability in technology, frequency of treatment, power and 
density settings, and concomitant laser-assisted drug delivery all present potential 
targets of study to optimize this approach. The ideal laser depth of penetration 
has been suggested to be 50-75% of the thickness of a scar by Isler-Fischer, et al., 
with depths of penetration outside this range offering little benefit [254]. Whether 
a difference exists between 50 and 75% depth of penetration is not known, nor 
whether these ranges are altered by various scar attributes, which may include scar 
age, patient age, scar vascularity, scar location, prior treatments, and more. Waibel, 
et al. introduced the use of optical coherence tomography (OCT) immediately prior 
to laser intervention to gauge the real time thickness of a given scar and optimiza-
tion of power settings based on these results [255]. This approach holds promise 
for patient- and scar-specific interventions, though clarity is lacking on whether 
optimal power based on scar thickness changes in a linear or non-linear way. 
Laser-assisted drug delivery frequently includes the application of TAC or 5-FU to 
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a clear advantage of one medication over the other, and continuing to optimize this 
technique is an area still available for future study [256]. The inherent variability in 
the administration of laser and light based technologies with and without the con-
comitant application of medications is a target for study in a clinical trial proposed 
out of UNC in 2018 [257]. The authors offer a flowsheet with proposed combina-
tions of the above with the goal of highlighting efficacy of different treatments and 
combinations thereof. Study designs such as these are sophisticated and are likely to 
assist in defining treatment guidelines from a large pool of differing approaches to 
laser scar revision.
5. Conclusion
The development of HTS is widespread after cutaneous traumatic injury and has 
profound effects on the quality of life of the patients who suffer from it. The vari-
ability between patients’ injury etiologies, wound locations, acute and long-term 
treatment approaches, medical comorbidities, and ethnicities makes research into 
the pathophysiology and treatment of HTS complex and multilayered. The combi-
nation of optimal modeling and broad patient representation in research is likely to 
afford improved translatability of future scientific discovery related to HTS.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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